Infarct size analysis
| Body Wt. | LV Wt. | AAR/LV | IS/AAR | |
|---|---|---|---|---|
| g | % | |||
| Control | 420 ± 15 | 0.76 ± 0.03 | 47.6 ± 4.4 | 60.6 ± 1.8 |
| IPC | 384 ± 13 | 0.72 ± 0.03 | 56.3 ± 1.8 | 8.2 ± 1.32-150 2-154 |
| TAN-67 | 400 ± 10 | 0.79 ± 0.04 | 56.5 ± 1.9 | 30.2 ± 2.42-150 2-151 |
| PD 098059 | 400 ± 17 | 0.88 ± 0.032-150 | 51.6 ± 2.5 | 67.0 ± 2.32-151 2-154 |
| PD 098059 + IPC | 395 ± 06 | 0.79 ± 0.02 | 55.0 ± 2.2 | 41.5 ± 6.42-150 2-151 |
| PD 098059 +TAN-67 | 368 ± 052-150 | 0.72 ± 0.03 | 51.6 ± 0.8 | 63.0 ± 4.82-154 |
Values given as mean ± S.E.M.
Body Wt., body weight in grams; LV Wt., left ventricular weight in grams; AAR/LV, area at risk expressed as a percentage of the left ventricle; IS/AAR, infarct size expressed as a percentage of the area at risk; IPC, preconditioning induced by 1 cycle of 5 min of ischemia and 5 min of reperfusion; TAN-67, δ1-opioid agonist infused for 15 min prior to ischemia and reperfusion; PD 098059, inhibitor of MEK, administered in the absence or presence of IPC or TAN-67.
↵2-150 p < 0.05 vs. control.
↵2-151 p < 0.05 vs. IPC.
↵2-154 p < 0.05 vs. TAN-67.